New technology G2 specifically affects the acne-causing Cutibacterium acnes bacteria strain to “significantly improve acne pathophysiology’ without affecting non-acneic C. acnes strains or staphylococci.
/PRNewswire/ Sequential Skin Inc. ("Sequential"), the skin microbiome company developing next generation non-invasive skin testing and data-driven solutions.
Zühlke collaborates with Sequential Skin to design and build a personalised microbiome skincare experience focused on digital scalability, security and quality.
LONDON and NEW YORK and SINGAPORE, June 29, 2022 /PRNewswire/ Sequential Skin Ltd, a leading skin genomics start-up, has been awarded an Innovate UK SMART Grant to fund a project on advancing current understanding of the skin microbiome in healthy and diseased skin - using their novel testing kits. Atopic dermatitis (AD) is a multifactorial chronic and recurrent inflammatory skin disease, affecting 20% of children and 10% of adults. Roughly 29% are moderate to severe cases, with healthcare and socio-economic costs of Pound 723M per year. This US $500k (equivalent to Pound 400k) project will be funded over 18 months to further the understanding of genetic and skin microbiome inputs, during disease progression, that may lead to helping to identify and stratify patients in the future. "We see a future where patients with recurrent and debilitating skin conditions are diagnosed in a highly precise way, at the point of care, which can then be followed by effective and targeted treatme
LONDON and NEW YORK and SINGAPORE, June 29, 2022 /PRNewswire/ Sequential Skin Ltd, a leading skin genomics start-up, has been awarded an Innovate UK SMART Grant to fund a project on advancing